Amneal Pharmaceuticals Files 8-K on Financials
Ticker: AMRX · Form: 8-K · Filed: Oct 30, 2025 · CIK: 1723128
Sentiment: neutral
Topics: financial-condition, results-of-operations, regulation-fd
Related Tickers: AMRX
TL;DR
AMRX dropped an 8-K detailing financial results and operations.
AI Summary
Amneal Pharmaceuticals, Inc. filed an 8-K on October 30, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Bridgewater, NJ.
Why It Matters
This 8-K filing provides crucial updates on Amneal Pharmaceuticals' financial performance and operational results, which can impact investor decisions and stock valuation.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Amneal Pharmaceuticals, Inc. (company) — Registrant
- October 30, 2025 (date) — Date of Report
- Bridgewater, NJ (location) — Principal executive offices
- 001-38485 (other) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Amneal Pharmaceuticals, Inc.'s results of operations and financial condition, as well as to include Regulation FD disclosures and financial statements and exhibits.
When was this 8-K filed?
This 8-K was filed on October 30, 2025.
Where are Amneal Pharmaceuticals, Inc.'s principal executive offices located?
Amneal Pharmaceuticals, Inc.'s principal executive offices are located at 400 Crossing Blvd, Bridgewater, NJ 08807.
What is the Commission File Number for Amneal Pharmaceuticals, Inc.?
The Commission File Number for Amneal Pharmaceuticals, Inc. is 001-38485.
What is the fiscal year end for Amneal Pharmaceuticals, Inc.?
The fiscal year end for Amneal Pharmaceuticals, Inc. is December 31.
Filing Stats: 691 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2025-10-30 06:19:05
Key Financial Figures
- $0.01 — stered Class A Common Stock, par value $0.01 per share AMRX The Nasdaq Stock Market
Filing Documents
- amrx-20251030.htm (8-K) — 28KB
- amrx-q32025ex991.htm (EX-99.1) — 523KB
- amneala.jpg (GRAPHIC) — 3KB
- 0001723128-25-000059.txt ( ) — 706KB
- amrx-20251030.xsd (EX-101.SCH) — 2KB
- amrx-20251030_lab.xml (EX-101.LAB) — 21KB
- amrx-20251030_pre.xml (EX-101.PRE) — 12KB
- amrx-20251030_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On October 30, 2025, Amneal Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the third quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The information in this report furnished pursuant to Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, October 30, 2025, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. To access the call through a conference line, dial (833) 470-1428 (in the U.S.) with access code 272787. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://www.netroadshow.com/events/global-numbers?confId=89042. The information in this report furnished pursuant to Item 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. The following exhibits are furnished herewith: Exhibit No. Description 99.1 Press release issued October 30, 2025. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025 AMNEAL PHARMACEUTICALS, INC. By: /s/ Anastasios Konidaris Name: Anastasios Konidaris Title: Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)